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Accumulating evidence suggests that long non-coding RNA H19 correlates with several
aging processes. However, the role of H19 in aging remains unclear. Many studies have
elucidated a close connection between H19 and inflammatory genes. Chronic systemic
inflammation is an established factor associated with various diseases during aging. Thus,
H19 might participate in the development of age-related diseases by interplay with
inflammation and therefore provide a protective function against age-related diseases.
We investigated the inflammatory gene network of H19 to understand its regulatory
mechanisms. H19 usually controls gene expression by acting as a microRNA sponge, or
through mir-675, or by leading various protein complexes to genes at the chromosome
level. The regulatory gene network has been intensively studied, whereas the biogenesis
of H19 remains largely unknown. This literature review found that the epithelial-
mesenchymal transition (EMT) and an imprinting gene network (IGN) might link H19
with inflammation. Evidence indicates that EMT and IGN are also tightly controlled by
environmental stress. We propose that H19 is a stress-induced long non-coding RNA.
Because environmental stress is a recognized age-related factor, inflammation and H19
might serve as a therapeutic axis to fight against age-related diseases.
Keywords: long non-coding RNA, H19, aging, inflammation, stress, signaling networkINTRODUCTION
Aging is characterized by multiple organ malfunctions, and is an inevitable biological process.
Chronic degeneration is a significant pathological phenomenon in various age-related diseases.
Inflammation is a part of the self-defense response to pathogens and its associated damage functions
in self-clearance mechanisms. Inflammation is also associated with age-dependent tumor
pathogenesis. Cancer incidence increases with age, and is maximal at > 65 years of age [1].
Continuous inflammatory responses lead to tumors by inducing cell overgrowth; therefore, cancer
has been regarded as a wound that never heals. Inflammation also leads to the pathogenesis of someorg October 2020 | Volume 11 | Article 5796871
Wang et al. H19 in Inflammation and Agingchronic diseases, such as diabetes, Alzheimer disease, chronic
kidney disease and osteoarthritis (1–4). Emerging evidence
suggests that inflammation also plays critical roles in tissue
regeneration by activating cell migration and proliferation or
clearing undesired cells. The interplay between inflammation
and tissue regeneration is complex. The effect of inflammatory
reactions on tissue regeneration can vary depending on
pathological stage (5, 6). During tissue repair, inflammation is
immediately initiated by recruiting essential cells and activating
aging-related inflammatory factors such as tissue necrosis factor
(TNF-a), soluble TNF receptor II (TNFRII), C-reactive protein,
interleukin (IL)-6, IL-18, IL-15, and adiponectin (7).
Nevertheless, the molecular mechanisms of inflammation
during aging remains elusive.
Long non-coding RNA (lncRNA) participates in regulating
diverse biological processes, and their roles in aging have
recently been focused. During aging, lncRNA modulate telomere
length, senescence, heterochromatin formation, proteostasis,
stem cell differentiation, cell cycle regulation, and intracellular
communication (8). H19 was first identified as an imprinting
lncRNA; it is abundantly expressed at the fetal stage and
repressed postpartum except in the skeletal muscle system (9),
where it controls the imprinting of a cluster of conserved genes that
contain H19 itself and insulin-like growth factor 2 (IGF2). Intensive
cancer studies have regarded H19 as an oncogene, so it might serve
as a therapeutic target in cancer treatment (10). Evidence also
suggests that H19 is a potential target of antiaging therapy. This
review summarizes the network of H19 that is involved in regulating
inflammation and aging.H19 INVOLVEMENT IN AGE-RELATED
DISEASES
H19 in Diabetes
The H19 is highly expressed in the fetus stage and adult skeletal
muscle. Both the levels of H19 in fetuses with maternal diabetes
and skeletal muscle of type 2 diabetes(T2D) patients decreased
strongly (11, 12). In T2D patients, the H19 reduces the glucose
intake via mir-let-7, inhibiting the expression of its essential
target genes like insulin receptor (insr) and lipoprotein lipase
(lpl) in skeletal muscle. (11)The expression of H19 is reduced in
fetuses with maternal diabetes in that they have more
methylation at the imprint control region (ICR) of H19-Igf2
which would enhance IGF2 and decrease H19 expression (12). In
other studies, the DNA methylation profile of H19 could pass
from diabetic mothers to offspring (13), implying that H19
expression is glucose-dependent.
H19 in Osteoarthritis and Rheumatoid
Arthritis
A negative regulatory role of H19 in inflammation has been
proposed (14). H19 reduces TGF-b mRNA expression via mir-
675, the encoding microRNA of H19 (15). Pro-inflammatory TGF-
b drives the immune response of mesenchymal stem cells through
smad3 (16). Thus, H19 might directly participate in theFrontiers in Immunology | www.frontiersin.org 2development of osteoarthritis (OA) though the TGF-b pathway.
On the other hand, H19 is significantly upregulated in patients with
osteoarthritis, whereas, its expression is suppressed by TNF-a and
IL-1b (14). Interleukin-1b and TNF-a downregulate the expression
of col2A1 and H19, indicating that H19 plays a positive role in
cartilage repair. Proliferative chondrocytes in growth plates have a
mesenchymal-like phenotype and lack epithelial surface markers.
Since proliferative chondrocytes represent an intermediate stage
between resting and hypertrophic chondrocytes, this temporary
change in the epithelial mesenchymal transformation (EMT) could
lead to endochondral calcification (17). Hence, H19 might
contribute to cartilage repair by regulating the EMT.
In rheumatoid arthritis (RA), Tie-1, the pro-inflammation
factor, is upregulated. Knockdown of Tie-1 in endothelial cells
induces the simultaneous upregulation of H19 and
downregulation of Toll-like receptor 2 (TLR2), indicating a
potential anti- role of H19. The polarized expression of H19
and TLR2 suggests a link between H19 and the Toll-like
signaling pathway (18). Physical and physiological stress
usually mobilizes the innate immune system to protect the
body from infection (19). Since the Toll-like receptor is
associated with the innate immune response, H19 might also
mediate stress-induced inflammation (20). Besides, The H19
inhibitor represses the proliferation and induce apoptosis of
synovial cells through Notch signaling pathway (21). Highly
expression of H19 is detected in the synovial tissue in RA
patients. MAPK, EKR1/2, and PI3K activity control the level of
H19. Especially, H19 transfected synovial fibroblast shows a
significant change in TIMP2 expression, which indicates that
H19 participates in extracellular remodeling in RA (22).
In summary, the role of H19 in arthritis is inflammation-related.
H19 may contribute inflammation development in arthritis
through interacting with the canonical inflammation pathway.
H19 in Cardiovascular Diseases
Cardiomyocyte hypertrophy is an age-related disease. The
selective clearance of senescent cells from the mouse heart
leads to a decrease in cardiac hypertrophy (23). An RNA-
sequencing analysis showed that H19 is upregulated in
hypertrophied cardiomyocytes. A cellular study found that
H19 inhibits hypertrophy factor through mir-675 by targeting
CaMKIId (24). Overexpressed H19 promotes mammalian target
of rapamycin (mTOR) phosphorylation and further inhibits
cardiomyocyte autophagy (25). Since mTOR activation
subsequently promotes inflammation, H19 might inhibit
cardiomyocyte hypertrophy through an inflammatory pathway.
H19 is abundant in the heart in adulthood. It correlates with
coronary artery disease. In cardiac ischemic, H19 is significantly
upregulated under hypoxia conditions resulting in inhibition of
Col1a1 and cardiac fibrosis (26). Cardiac hypertrophy and fibrosis
correlate with aging-associate inflammation. In a cardiovascular
infraction, H19 plays a protective role in fighting against these two
aging-associated cardiac dysregulations.
On the contrary, H19 is repressed in the brain after birth. In
ischemic stroke, H19 promotes M1 microglial polarization, which
results in neuroinflammation (27). In atherosclerosis, another
subtype of stroke, H19 promoting ACP5 protein and increasedOctober 2020 | Volume 11 | Article 579687
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play an adverse role in neurogenesis by decreasing the expression
of Notch1 by inactivating the transcriptional activity of p53 (29). It
has been proved that H19 polymorphisms correlate with the
susceptibility ischemic stroke (30).
Cardiac fraction and ischemic stroke are all lead to hypoxia
condition. These two diseases induce high expression of H19, but
the role of H19 seems opposite between the brain and heart.
H19 in Cancer
Cancer and aging are interrelated because aging is thought to be
either pro-tumorigenic by regulating inflammation or tumor-
suppressive by inducing cellular senescence. A chronic
inflammatory environment promotes tumorigenesis, which
involves various inflammatory factors, such as IL-6 and TNF-a
(31). H19 is regarded as an oncofetal lncRNA and its
upregulation in various cancers has been speculated (32). For
example, H19 sponges let7a/let7b then mediate oxidative stress-
induced IL-6 expression in cholangiocarcinoma (33, 34). In
breast cancer, upregulation of H19 sponges with miR-152
promoting the proliferation and invasion of cancer cells via
upregulating of DNMT1 (35). Indeed, the downregulation of
H19 suppresses the expression of P53 that is involved in cell cycle
regulation (36). In gastric cancer, downregulation of H19
associates with p53 which to target BAX inhibiting cell growth
and inducing cell apoptosis in the AGS cell line (37). In the early
years, scientists have tried to establish a unified theoretical model
to describe the function of H19 in every stage of cancer. In cancer
initiation, H19 responds to stress conditions such as reduced P53
and hypoxia, then further activates tumorigenic and supports
tumor cell survival. H19 coordinates EMT (epithelial
mesenchymal transition) to promote tumor metastasis. H19
even supports MET (mesenchymal epithelial transition) to
promote tumor proliferation and colonization either in
primary or in the secondary site (38). P53 and EMT are
actually the core member of cancer development. This model
is easy to follow and understand. It only covers the general
function of H19. However, H19 has been widely studied in
cancer. It is hard to establish a sample model to describe H19
while considering various specific cancer types. A recent study
has analyzed the role of H19 in 24-types of cancer. Base on
Cancer Genome Atlas (TCGA) pan-cancer datasets, they
specifically examined H19 in pan-cancers and confirm that
H19 mediates transcription factors as a microRNA sponge,
various new H19 mediated TFs have been discovered (39).
However, until now, the whole picture of causality between
H19 and cancer remains unclear The bioinformatics analysis
may provide a feasible paradigm to understand the role of H19
from a more comprehensive angle. whether H19 controls the
inflammation response in tumors remains ambiguous.
To date, no direct evidence has shown that higher levels of
H19 expression delays aging. Table 1 summarizes recent studies
of H19 in age-related disease. H19 is notably upregulated in all
the listed age-related diseases in which inflammation plays a
crucial role except Type II diabetes. Abnormal H19 expression in
various age-related diseases, indicating that H19 could serve as a
therapeutic target for preventing age-related diseases.Frontiers in Immunology | www.frontiersin.org 3INTERPLAY BETWEEN H19 AND
INFLAMMATION
Accumulating evidence indicates that H19 might be an age-
associated long non-coding RNA. The relationship between H19
and inflammation is unclear. H19 regulates the gene network of
canonical inflammatory pathways including those of NFkB, p38/
MAPK/mTOR, toll-like receptor, and TNF-a. H19 is a positive
regulator of inflammation and it can activate NF-kB by regulating
the expression of thioredoxin (42). H19 also has proinflammatory
effects in atherosclerosis by enhancing p38 expression, which is a
central modulator of the MAPK and NF-kB pathways (43). H19
sponges let7a/let7b then mediate oxidative stress-induced IL-6
expression in cholangiocarcinoma (44).
H19 and mTOR mediate PI3K and stat3 signaling, whereas
stat3 is believed to promote inflammation in several diseases
(45) . The overexpress ion of H19 promotes mTOR
phosphorylation that will result in suppressing the activity of
mTOR and inhibiting cardiomyocyte autophagy (25). Similar
regulation is also evident in keloid scarring, where H19 promotes
the development of fibroblasts via the suppression of mTOR
(46), which is regarded as a core target in anti-aging research.
Many studies have examined the suppression of mTOR signaling
to mimic the signaling of rapamycin and the phosphatase and
tensin homolog (PTEN) pathway. Inflammation and
hyperactivated mTOR are often associated (47), and thus H19
could be a potential suppressor of aging-related inflammation by
suppressing mTOR activity. Interactions between H19 and
pathways of inflammation are controversial. H19 promotes
inflammation through several pathways and inhibits
inflammation by suppress ing mTOR. However , we
summarized the literature and highlighted two groups of genes
that might contribute to mediating H19 and inflammation to
help further understand how H19 regulates inflammation.
H19 Mediates Inflammation by Controlling
the EMT
Inflammation Induces EMT
The EMT is involved in a multitude of biological processes,
including embryonic development, wound healing, fibrosis, and
cancer metastasis. Several markers have been identified that
indicate transitional stages (48). Inflammatory factors attract
cells from adjacent tissues, including neutrophils, macrophages,
fibroblasts, and stem cells during the early phase of woundTABLE 1 | Expression of H19 in various diseases.
Tissue Disease Pathological
expression
Relevant
Signaling
Muscle (11) Type II diabetes Down PI3K/AKT
Cartilage (14) Osteoarthritis Up Sox9/
col2A1
Synovial Tissue (22) Rheumatoid arthritis Up MKK/JNK
Umbilical cord
blood (40)
Obesity Up N/A
Plasma (41)
Heart (24)
Gastric cancer
Cardiomyocyte
hypertrophy
Up
Up
N/A
CaMKIIdOctober 2020 | Volume 11 | Article 579687
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migration. Fibrosis is a complication of wound healing caused
by the excessive accumulation of fibroblast-secreted extracellular
matrix and it is a major cause of dysfunctional injured tissue.
Inflammatory factors are the major players during the early
phase of fibrosis (49). Bone morphogenetic protein receptor, type
IA (BMPR1A) mediates TNF-a-induced EMT in the skin and
primary keratinocytes, indicating that smad1/5/8 signaling is also
involved in inflammation-induced EMT (50).
Although the etiology of fibrosis is complex and tissue-
specific, the EMT frequently occurs during the chronic
inflammation-induced fibrosis of various tissues (51). The
EMT also contributes to the progression and metastasis of
cancer cells, and is involved in suppressing cell senescence and
in developing resistance to radiotherapy and chemotherapy (52,
53). The EMT marker gene, snail2, can be stabilized through
nuclear factor kappa B (NFkB) activation revealing a possible
role of EMT in inflammation-induced cell migration (54). The
activity of AKT/GSK-3b is required to stabilize snail in the TNF-
a-induced EMT and metastasis (55)in colorectal cancer. In
summary, because EMT is a downstream event of chronic
inflammation, understanding the role of H19 in inflammation
and how it interacts with EMT is imperative.
H19 Interacts With EMT by Regulating MicroRNA or
Directly Controlling Epigenetic Modification
Many studies have indicated a relationship between H19 and
EMT. H19 acts in colorectal cancer as a microRNA sponge for
MiR-138 and MiR-200, which then target zinc finger e-box
binding homeobox 1 (ZEB1) and ZEB2 that are important
mesenchymal cell markers in EMT (56). H19 promotes the
migration of pancreatic cancer cells by sponging let7, then
targeting the EMT inducer, high mobility group AT-hook 2
(HMGA2) (57). Treating gallbladder carcinoma with TGF-b1
and IL-6 induces the expression of H19, which in turn,
downregulates the protein abundance of E-cadherin and
subsequently promotes the EMT (58). H19 exerts an inhibitory
role on E-cadherin by binding to EZH2 (59)in bladder cancer.
In contrast, H19 can reverse the EMT and the migration of
hepatocellular carcinoma cells by promoting expression of the
MiR-200 family (60). Inconsistencies among experimental
models and conditions resulted in conflicting data about
regulation between H19 and EMT. H19 might either induce or
reverse the EMT independently of EMT inducers. The
expression of slug activated by TGF-b contributes to the H19/
EMT regulatory axis by inhibiting MiR-200 that prevents H19
activation. Because H19 is an EMT inducer only when no other
signals intervene, H19 might not be the exclusive decisional
factor in EMT but will function like other EMT enhancers (61).
H19 might have similar functions as an EMT in mediating the
inflammatory response. H19 also has opposing functions in the
regulation of inflammation. H19 overexpression usually leads to
enhanced expression of the p38/MAPK/NFkB pathway while
directly suppressing mTOR/STAT3 pathway. The role of H19 in
inflammation depends on context. Like its role in EMT, the
function of H19 might shift according to changes in extracellularFrontiers in Immunology | www.frontiersin.org 4signals. H19 might activate inflammatory processes during
wound healing together with EMT activation but suppress
inflammation through the mTOR pathway in chronic
systemic inflammation.
H19 Interacts With Inflammation Through
an Imprinted Gene Network (IGN)
A discussion of the role of H19 in an imprinted gene network
(IGN) requires the introduction of the important insulin-like
growth factor 2 (IGF2) gene. A classical modulation model exists
between IGF2 and H19 because they are located in a nascent
manner and each affects the function of the other through
epigenetic regulation.
Interaction Model Between IGF2 and H19
As an imprinting gene, H19 co-regulates with the fetal-specific
IGF2 gene, and its expression depends on the methylation level
on the flanking sequence of H19 (62).
The Igf2/H19 DMR is conserved among mammals including
rats, mice and humans (63). H19 and IGF2 are usually paired
because they are located next to each other at the same locus.
This locus regulates the imprinting network while expression
from parents is unbalanced. In this locus, the IGF2 and DLK1
genes come from a paternal allele, while H19, IGF2R, and
SNRPN are maternally inherited. Insulin-like growth factor 2
functions is a positive regulator of metabolism and embryo
growth (64). Current understanding of H19 is limited to its
function as a non-coding RNA due to the lack of an open reading
frame at the genomic level (65). H19 could simultaneously
function as a tumor suppressor and an oncogene (32, 33, 66–
69). H19 expression is regulated through the DNA methylation
of its promoter. The expression of H19 and IGF2 differentially
depend on the methylation status of ICR or DMR that are located
upstream of H19 (70). Two theoretical models of the interaction
between IGF2 and H19 in the DMR have been proposed. One is
the enhancer competition model in which an enhancer is
proposed downstream of the H19 locus to interact with IGF2
and H19. On the paternal allele, DMR is hypomethylated to
prevent binding of the insulator protein CCCTC-binding factor
(CTCF) (70). On the maternal allele, CTCF-disrupted
interaction between IGF2 and its enhancer would lead to
increased H19 expression. The other is the boundary model in
which the three-dimensional structure of chromosome has been
applied to illustrate CTCF regulation. The CTCF directly binds
to the distal enhancer, which blocks IGF2 expression and cohesin
stabilizes the binding (71). The CTCF plays a leading role in the
regulation of H19 expression regardless of the model. Affecting
the function is CTCF on several loci or directly altering CTCF
expression at transcriptional level is crucial to H19 regulation.
H19 Negatively Controls the IGN
The coordinated IGN controls embryonic growth and
development. This network contains maternal and paternal
alleles, as well as growth-promoting and inhibiting genes.
Expression levels among IGN rarely exceed 35%, indicating
that unknown feedback mechanisms or extremal signalingOctober 2020 | Volume 11 | Article 579687
Wang et al. H19 in Inflammation and Agingfrom another network might be involved in IGN-regulated
growth control (72). Meanwhile, expression of the IGN is
downregulated holistically during the postnatally delayed
growth at the somatic cell stage (73).
The imprinting gene, H19, controls the IGN, and MBD
interacts with H19 to form a ribonucleoprotein complex that
recruits histone lysine methyltransferases that suppress gene
expression. Through this interaction, H19 increases levels of
H3K9me3 at the DMR of other imprinting genes, including Igf2,
Mest (Peg1) and Slc38a4, and suppresses IGF2 through MiR-675
(74, 75). The IGN genes, Igf2, Dlk1, Cdkn1c, Dcn, Peg3, and
Mest, are upregulated during muscle injury and they can also be
reassembled on the IGN in H19 knockout mice (76). H19 is a
beneficial regulatory factor that can mediate the injury process by
suppressing IGN expression. The activation of IGN after muscle
injury raises the question of the role played by IGN in tissue
regeneration, since inflammation is the first phase of this process.
The IGN might control inflammatory signaling at the cellular
level and contribute to the signaling of cells that response to
extracellular stress.
The intermediate role of IGN between aging and
inflammation has not been discussed and reviewed, but the
interplay between inflammation and IGN core genes has been
studied. Paternally expressed gene 3 (Peg3) reportedly helps to
activate NFkB by binding with TRAF2, which is the cascade
factor required to mediate the TNF-a-induced inflammatory
response (77). Oxidized low-density lipoprotein (ox-LDL)
stimulates elevated IGF2 expression and mediates the
activation of IL6 and NFkB (78). Oxidative stress-induced loss
of imprinting (LOI) of IGF2 is mediated through NFkB
activation, and the binding of NFkB with CTCF indicates that
NFkB helps to block CTCF from the H19 DMR (79). The
interaction between NFkB and IGF2 might also contribute to
abnormal age-related inflammation. Indeed, IGF2 and mTOR
could have positive feedback regarding their own functions. The
key target of mTOR in myogenesis is IGF2 and mTOR would
directly regulate IGF2 expression through suppressing mir-125b
(80). Not only is IGF2 activated by mTOR at a muscle-enhancer
via a kinase-independent pathway (80) but it is also involved in
tumorigenesis by binding to the upstream receptor, IGF1R, in the
PI3K/AKT/mTOR pathway (81). Decorin is a proinflammatory
ECM protein and its binding network has been summarized;
decorin reduces IL-10 levels via micro-21 and protocadherin
alpha gene cluster (PCDA) 4 in cancer cells (82). The abnormal
expression of decorin in tendon development and repair leads to
compromised mechanical properties of tendons with age (83).
Another key gene in the network is a cyclin-dependent-kinase
inhibitor (CDKN1C; p57), which is enhanced in an LDL-induced
chronic inflammatory model (84). Thus, IGN might positively
regulate inflammation signaling via IGF2 signaling. As in the
IGF2/H19 model, increased IGF2 expression usually leads to
suppressed H19 expression. In contrast, the LOI of IGF2
increases age-associated IGF2 expression (79, 85). Age-related
LOI at the DMR in a maternal chromosome would induce
abnormally high IGF2 expression, which might be involved in
the higher incidence of cancer among elderly populations (86).Frontiers in Immunology | www.frontiersin.org 5The expression CTCF and its binding at the DMR are decreased in
age-related cancer and cellular senescence (79, 87, 88). This
indicates that H19 expression might decline with advancing age.
Even though the relationship between IGN and inflammation has
not yet been comprehensively reviewed, several imprinting genes
are important for the positive regulation of inflammatory gene
expression. Thus, H19 could negatively regulate the expression of
these genes and subsequently mediate the inflammatory process.
Additionally, since imprinting genes participate in growth control
and aging, H19 should play a pivotal role in age-
related inflammation.MOLECULAR MECHANISMS
CONTROLLING H19 EXPRESSION
H19 could be a potential therapeutic target of anti-aging by
controlling inflammation. How the H19 expression is controlled
must be understood before it can be manipulated. The regulatory
mechanisms of H19 are currently under investigation and review.
Unlike coding genes, the H19 locus lacks a promoter region,
indicating that a unique mechanism decides its expression level.
CCCTC-Binding Factor (CTCF) Controls
H19/IGF2 Locus
Among these binding genes, the polycomb repressive complex 2
subunit (SUZ12) reassures the relationship between PRC2 and
H19 expression. Poly (ADP-ribose) polymerase-1 (Parp-1) is
involved in transcriptional regulation by modulating the
chromatin structure, and H19 is upregulated in Parp-/- ES
cells (89). Among the genes introduced into the binding
network, mothers against decapentaplegic homolog (SMAD) 2
and SMAD3 are the key downstream regulators of TGF-b
signaling. The CTCF-smad complex might function in the
organization of chromatin cross-talk and this complex could
provide hints regarding smad3 and CTCF binding (90). Small
ubiquitin-like modifier (SUMO)3 is included in the network and
this indicates that sumoylation, an important post-translational
modification, also contributes to changes in the location or
binding partner(s) of CTCF. The sumoylation of CTCF occurs
near the c-myc P2 promoter (91). Although no direct evidence
shows that CTCF bis sumoylated the H19 DMR, hypoxic stress
induces desumoylation on CTCF and H19 upregulation (92). In
addition, H19 RNA is upregulated under hypoxic stress (93).
Sumoylation might act as a positive H19 regulator under
hypoxia. The presence of UBE2I and UBC9 indicates that
sumoylation on CTCF might proceed through the recruitment
of the ubiquitin conjugating enzyme UBE2I (94). The SIN3A/
HDAC complex is recruited to NKX3.2, a cartilage repressor, and
the binding of CTCF and SIN3A implies the participation of H19
in cartilage development (95). The interaction between RNA
polymerase II (POLR2A) and CTCF might explain why H19 is
upregulated when CTCF binds to the upstream DMR of H19.
The key proteins YBX1 and TAF1 can mediate the RNA
polymerase II complex (96).October 2020 | Volume 11 | Article 579687
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epigenetic regulation, might play a key role in H19
modulation. Sumoylation is another important epigenetic
modification that has the potential to alter H19 expression.
The involvement of CTCF in regulating the activities of H19
on DMR indicates that H19 participates in a broad spectrum of
cellular events.
H19 Is a Stress Induced lncRNA
H19 and the inflammatory response are closely associated in the
signaling network, yet the physiological role of H19 remains a
matter of debate. H19 is apparently a stress-induced lncRNA, the
expression of which changes in response to serum starvation and
hypoxia stress-induced cell proliferation. These findings suggest
that H19 mediates stress-induced tumor growth (97). However,
whether the activation of H19 is detrimental or beneficial (97).to
somatic cells is difficult to determine Stress-induced epigenetic
regulation promotes H19 expression and audio stress on
embryos results in the loss of methylation at the H19 locus,
which leads to upregulated H19 expression (98). One study
found relatively lower methylation levels on the H19 locus of
epigenetic newborn twins derived from in vitro fertilization
(IVF). Although IVF-induced stress has not been clearly
defined, extracellular stress is sufficient to affect the epigenetic
profile of H19 even after the long-term conception stage (99).
Most study findings agree that H19 is an lncRNA that is
expressed by the fetus and becomes suppressed after birth. The
EST profile extracted from the NCBI database (https://www.ncbi.
nlm.nih.gov/) (Figure 1) indicates that H19 expression does have
another peak in adult humans. These data suggest that H19
becomes expressed and accumulated when adult humans are
exposed to environmental stress (97).
The biological functions of the stress induced H19 gene in
cellular responses remains unclear. However, considering the
enhanced proliferation of stressed cells in serum, H19 might play
a protective role. Acute inflammation helps tissue regeneration,Frontiers in Immunology | www.frontiersin.org 6while chronic inflammation might result in irreversible tissue
injury. The expression of H19 is related to inflammation and
corresponds to its function in tissue regeneration. The immediate
post-injury elevation of H19 might help the migration and
proliferation of cells at wound sites, and it is coordinated with
inflammation at the early phase of regeneration. Since persistent
activation of H19 might be a key factor in age-related
tumorigenesis, H19 might similarly contribute to tumor
growth and inflammation associated with aging.
Epigenetic Regulation of H19
Since expression of the IGF2/H19 locus is based on the amount
of DNA methylation at the DMR, the participation of DNA
methyltransferases de novo or maintenance methylation are
reasonable. Demethylases are also involved in regulating
methylation, and several studies have shown that DNMT1
affects H19 expression in knockout mice and mouse models of
overexpression (100, 101).
Either DNMT3a or DNMT3b knockout cells have
hypermethylated H19 at the DMR, but not when DNMT3A/3B
signals are knocked out (102). Besides, incubating cells with the
methyltransferase inhibitor, 5-aza-2-deoxycytidine, reduces
DMR methylation (103). The ten-eleven translocation (TET)
family is also involved in the regulation of H19 methylation,
because H19 demethylation in the ICR was removed when
spermatogonia stem cells from Tet1 and Tet2 double knockout
mice were reprogrammed (104).
Several important histone markers enriched around the H19
DMR during histone modification are associated with changes in
H19 expression such as H3K9ac, H3K4me, H3K27me, and
H3K9me (105–107). Levels of H3K9me2, which is the
hallmark of silent chromatin, are increased around CTCF
binding sites in mutant maternal alleles (108). The reduced
H3K9me3 at the H19 promoter region promotes H19
expression in lung cancer cells (109). The overexpression of
histone protein H3.1 linking to increased methylation at the
DMR (110). These findings suggested that histone modification’s
classical covenant model can be applied to H19 regulation at the
chromatin level (111). Since repressive histone modification
could be enriched around H19, the components of polycomb
repressive complexes (PRC) might be linked to H19 expression.
Maintenance of embryonic stem cells’ undifferentiated status
requires the PRC 2 subunit (SUZ12), and SUZ12-deleted cells
tend to have a global loss of H3K27me3 and significantly
increased H19 express ion (112) . Another hi s tone
methyltransferase, SUV39h2, directly inhibits H19 expression
in ovarian cancer (113). In addition, the acetylation of histones
H3 and H4 affect the imprinting of the IGF2/h19 locus. This
regulation is controlled by the chromatin condensation status,
indicating that H3K9 methylation is also involved in H19
regulation (107). The expression of H19 depends on how the
IGF2/H19 locus is modified according to the CTCF binding
network, and several modifications might affect the level of H19
expression. These modifications have never been determined in
age-related studies of H19 as a downstream target.FIGURE 1 | H19 EST profiile across developmental stage.October 2020 | Volume 11 | Article 579687
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Epigenetic Regulation
The non-coding RNA, H19, functions differently from coding
genes. H19 might regulate inflammatory signaling as a
microRNA precursor, a microRNA sponge or a chromatin
structure modulator. H19 was originally identified as an
endogenous RNA precursor of microRNA-675 during 2009
(114). H19 suppresses gene expression by overexpressing MiR-
675 and inhibiting the post-transcriptional expression of target
genes. H19 can block the TGF-b inhibitor, MiR-29b, during
tenogenic differentiation (115). H19 facilitates the EMT by
sponging MiR-138 and MiR-200a to promote ZEB1 and ZEB2
in colorectal cancer (56). These findings indicated that H19
functions as a competing endogenous RNA.
Apart from targeting microRNA, the H19 silencing gene can
alter H3K9me3 or H3K27me3 histone modifications by
recruiting the repressive chromatin modification complex. This
salient chromatin structure suppresses the expression of nascent
genes. H19 can interact with the PRC2 complex, such as by
binding to the enhancer of Zeste 2 polycomb Repressive complex
2 subunits (EZH2) in cancer cells (59). H19 also binds methyl-
CpG-binding domain protein 1 (MBD-1) in muscle cells when it
does not form complexes with EZH2 or G9A (74). The difference
in EZH2 binding indicates that the binding affinity of H19 and
histone methyltransferase is tissue- or time-specific. The
mechanism of the differential binding of H19 and EZH2 and
the regulating factors involved in H19 functions in this binding
have not yet been addressed. H19 might guide the recruitment of
epigenetic modifiers to their DNA targets. How H19 chooses the
target and whether the lncRNA has a distinct target profile
remain elusive.Frontiers in Immunology | www.frontiersin.org 7We concluded all the signaling networks mentioned in this
review are a schematic diagram, which demonstrates the
upstream and downstream signaling to summarize and to
provide a comprehensive understanding of the regulation of
H19 (Figure 2).CONCLUSION AND PERSPECTIVE
This review summarized the existing evidence of the expression
trend of H19 during various age-related diseases. We discover a
potential intermediate role of H19 correlated with the mentioned
diseases. We then investigate the inflammatory gene network of
H19 to understand its regulatory mechanisms. The literature
review indicates epithelial-mesenchymal transition (EMT) and
imprinting gene network (IGN) might link inflammation and
H19. Our study also found that H19 is a stress-induced lncRNA.
Because environmental stress is a recognized age-related factor,
inflammation and H19 might serve as a therapeutic axis for age-
related disease. The current review only focuses on the regulatory
role of H19 in inflammation and aging. Due to H19 also control
or participate in a broad spectrum of biological process. We
proposed the following directions, in which H19 might also
contribute to their functions.
A Potential Therapeutic Strategy in
Aging-Related Disease, Targeting H19
Controlled Cell Differentiation Through
Inflammation Signaling
When we are getting old, body repair and tissue functions
compromise due to the dysfunction of onsite stem/progenitorFIGURE 2 | Schematic diagram of regulating H19 signaling network.October 2020 | Volume 11 | Article 579687
Wang et al. H19 in Inflammation and Agingcells. Age-associated inflammation is the main reason for stem
cell dysfunction. This linkage is mediated by NF-kB and another
inflammation signaling (116, 117). H19 promotes the osteogenic
differentiation of osteoblast cells through the MiR-675/smad3
pathway. Meanwhile, MiR-675 downregulates the expression of
histone deacetylase (HDAC) 4/5, a smad3-recruited histone
modifier that is involved in osteoblast differentiation (118).
Through MiR-675, H19 directly inhibits HDAC4/5/6 expression
in the adipogenic differentiation of bone marrow-derived
mesenchymal stem cells. Meanwhile, forced expression of H19
also reduces the expression of CEBP-a and PPAR-g that are
important regulators of adipogenesis and inflammation (119).
Obesity and metabolic dysfunction are thought to be associated
with low-grade chronic inflammation and supporting evidence
has been summarized (120). H19 might contribute to stem cell
adipogenesis differentiation by regulating inflammatory cascades
and then affecting the adipocyte metabolic functions. H19 might
be considered as a potential anti-aging signaling target through
the modulation of inflammation. Then further contribute to
disease treatment through control cell differentiation.
Role of H19 in Inherited Diseases, a
Potential Direction to Understand the
Relationship Between Inflammation,
Aging, and Environmental Stimulus
Levels of H19 expression are usually high in inflammation-
related diseases. H19 expression is abnormal in synovial tissues
from patients with RA (22) and cartilage from those with OA
patients (14). H19 is regarded as an inflammation-induced
lncRNA that plays anabolic and protective roles in RA andFrontiers in Immunology | www.frontiersin.org 8OA, and DNA methylation at the H19 locus might be reduced
by inflammatory stress (14). Due to the hereditary nature of RA
and OA, long term systematically-induced energetic changes in
H19 might contribute to the susceptibility of future generations
to arthritis (72). Both RA and OA are age- and inflammation-
related degenerative diseases. Investigating possible roles of H19
in these two diseases might provide further insight into how H19
regulates inflammation in response to environmental cues or
even hereditary factors associated with aging.AUTHOR CONTRIBUTIONS
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